Table 1.
Baseline Clinical Characteristics of Patients.
| Carvedilol |
p-value* | ||||
|---|---|---|---|---|---|
| Placebo (n = 38) | 6.25 mg (n = 41) | 12.5 mg (n = 38) | 25 mg (n = 37) | ||
| Age (yrs) | 40.4 ± 14.0 | 46.1 ± 13.0 | 41.3 ± 18.2 | 42.0 ± 15.0 | 0.345 |
| Women (%) | 76 | 80 | 58 | 77 | 0.119 |
| BMI (kg/m2) | 27.4 ± 6.5 | 29.1 ± 6.3 | 27.1 ± 6.4 | 28.3 ± 7.2 | 0.511 |
| Baseline EF (%) | 62.0 ± 4.6 | 61.4 ± 3.9 | 60.0 ± 4.2 | 60.5 ± 4.2 | 0.177 |
| LVDd (mm) | 45.3 ± 5.3 | 46.0 ± 5.1 | 44.8 ± 4.3 | 44.6 ± 6.3 | 0.634 |
| LVSd (mm) | 28.0 ± 4.4 | 29.3 ± 4.4 | 29.2 ± 4.2 | 30.2 ± 5.7 | 0.243 |
| E/A (%) | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.3 ± 0.5 | 1.2 ± 0.3 | 0.836 |
| E' | 11.3 ± 3.0 | 11.9 ± 3.2 | 13.2 ± 5.1 | 11.8 ± 3.4 | 0.150 |
| DT | 190.8 ± 33.8 | 200.6 ± 28.2 | 203.6 ± 38.7 | 199.5 ± 38.8 | 0.421 |
| E/E' | 7.2 ± 2.6 | 7.4 ± 3.0 | 7.0 ± 3.3 | 6.9 ± 2.6 | 0.836 |
| Cancer Type (%) | |||||
| Breast | 20 (53) | 23 (56) | 13 (34) | 16 (43) | 0.208 |
| NHL | 5 (13) | 8 (20) | 11 (29) | 12 (33) | 0.177 |
| Other | 13 (34) | 10 (24) | 14 (37) | 9 (24) | 0.502 |
| Cum Doxo dose (mg/m2) | 265.6 ± 98.5 | 252 ± 65.0 | 282 ± 78.5 | 261.0 ± 101.8 | 0.473 |
| Hypertension | 4 | 4 | 3 | 7 | 0.524 |
| Diabetes Mellitus | 6 | 8 | 5 | 8 | 0.712 |
| Dyslipidemia | 2 | 0 | 3 | 3 | 0.267 |
Data are mean ± standard deviation or percentage. Cum Doxo dose and NHL denote cumulative doxorubicin dose and Non-Hodgkin Lymphoma respectively.
*
P-value by ANOVA for continuous variables and Chi Square or Fisher’s test for categorical variables.